Discloses use of an anti-adrenomedullin antibody or an anti-ADM antibody fragment binding to adrenomedullin or an anti-ADM non-Ig-protein scaffold binding to adrenomedullin in the manufacture of a medicament, wherein said antibody or fragment or scaffold binds to the N terminal part, amino acids 1 to 21, of adrenomedullin: YRQSMNNFQGLRSFGCRFGTC SEQ ID No. 23.